Although many novel agents, such as pembrolizumab, topoisomerase-1-inhibiting antibody–drug conjugate (ADC) targeting Trop-2 (sacituzumab govitecan), temozolomide, and antibody–drug conjugate directed against delta-like protein 3 (rovalpituzumab tesirine), have been tested for their toxicity and clinical efficacy in recurrence or resistant small cell lung cancer28–31, studies of novel agents in neuroendocrine carcinoma of other sites is limited. Here, DLL3 is linked to neuroendocrine carcinoma.